Hubbry Logo
HypothyroidismHypothyroidismMain
Open search
Hypothyroidism
Community hub
Hypothyroidism
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Hypothyroidism
Hypothyroidism
from Wikipedia

Hypothyroidism
Other namesUnderactive thyroid, low thyroid, hypothyreosis
Molecular structure of the thyroxine molecule
Molecular structure of thyroxine, which is deficient in hypothyroidism
Pronunciation
SpecialtyEndocrinology
SymptomsFatigue (feeling tired), poor ability to tolerate cold, muscle aches, constipation, weight gain,[3] depression, anxiety, irritability[4]
ComplicationsDuring pregnancy can result in cretinism in the baby[5]
Usual onset> 60 years old[3]
CausesHashimoto's thyroiditis, thyroiditis, surgical removal of thyroid gland, iodine deficiency, lithium treatment[3]
Diagnostic methodBlood tests (thyroid-stimulating hormone, thyroxine)[3]
Differential diagnosisDepression, dementia, heart failure, chronic fatigue syndrome[6]
PreventionSalt iodization[7]
TreatmentLevothyroxine[3]
Frequency0.3–0.4%[8]

Hypothyroidism is an endocrine disease in which the thyroid gland does not produce enough thyroid hormones.[3] It can cause a number of symptoms, such as poor ability to tolerate cold, extreme fatigue, muscle aches, constipation, slow heart rate, depression, and weight gain.[3] Occasionally there may be swelling of the front part of the neck due to goiter.[3] Untreated cases of hypothyroidism during pregnancy can lead to delays in growth and intellectual development in the baby or congenital iodine deficiency syndrome.[5]

Worldwide, too little iodine in the diet is the most common cause of hypothyroidism.[8][9] Hashimoto's thyroiditis, an autoimmune disease where the body's immune system reacts to the thyroid gland,[10] is the most common cause of hypothyroidism in countries with sufficient dietary iodine.[3] Less common causes include previous treatment with radioactive iodine, injury to the hypothalamus or the anterior pituitary gland, certain medications, a lack of a functioning thyroid at birth, or previous thyroid surgery.[3][11] The diagnosis of hypothyroidism, when suspected, can be confirmed with blood tests measuring thyroid-stimulating hormone (TSH) and thyroxine (T4) levels.[3]

Salt iodization has prevented hypothyroidism in many populations.[7] Thyroid hormone replacement with levothyroxine treats hypothyroidism.[3] Medical professionals adjust the dose according to symptoms and normalization of the TSH levels.[12] Thyroid medication is safe in pregnancy.[3] Although an adequate amount of dietary iodine is important, too much may worsen specific forms of hypothyroidism.[3]

Worldwide about one billion people are estimated to be iodine-deficient; however, it is unknown how often this results in hypothyroidism.[13] In the United States, overt hypothyroidism occurs in approximately 0.3–0.4% of people.[8] Subclinical hypothyroidism, a milder form of hypothyroidism characterized by normal thyroxine levels and an elevated TSH level, is thought to occur in 4.3–8.5% of people in the United States.[8] Hypothyroidism is more common in women than in men.[3] People over the age of 60 are more commonly affected.[3] Dogs are also known to develop hypothyroidism, as are cats and horses, albeit more rarely.[14] The word hypothyroidism is from Greek hypo- 'reduced', thyreos 'shield', and eidos 'form', where the two latter parts refer to the thyroid gland.[15]

Signs and symptoms

[edit]

People with hypothyroidism often have no or only mild symptoms. Numerous symptoms and signs are associated with hypothyroidism and can be related to the underlying cause, or a direct effect of not having enough thyroid hormones.[16][17] Many symptoms of hypothyroidism are otherwise common and do not necessarily indicate thyroid problem.[3] Hashimoto's thyroiditis may present with the mass effect of a goiter (enlarged thyroid gland).[16] In middle-aged women, the symptoms may be mistaken for those of menopause.[12]

Symptoms and signs of hypothyroidism[16]
Symptoms[16] Signs[16]
Fatigue Dry, coarse skin
Feeling cold Cool extremities
Poor memory and concentration Myxedema (mucopolysaccharide deposits in the skin)
Constipation, dyspepsia[18] Hair loss, Sign of Hertoghe
Weight gain with poor appetite Slow pulse rate
Shortness of breath Swelling of the limbs
Hoarse voice Delayed relaxation of tendon reflexes
In females, heavy menstrual periods (and later light periods) Carpal tunnel syndrome
Abnormal sensation Pleural effusion, ascites, pericardial effusion
Poor hearing
Muscle weakness

Delayed relaxation after testing the ankle jerk reflex is a characteristic sign of hypothyroidism and is associated with the severity of the hormone deficit.[8]

Myxedema coma

[edit]
Man with myxedema or severe hypothyroidism showing an expressionless face, puffiness around the eyes, and pallor
Additional symptoms include swelling of the arms and legs and ascites.

Myxedema coma is a rare but life-threatening state of extreme hypothyroidism. It may occur in those with established hypothyroidism when they develop an acute illness. Myxedema coma can be the first presentation of hypothyroidism. People with myxedema coma typically have a low body temperature without shivering, confusion, a slow heart rate and reduced breathing effort. There may be physical signs suggestive of hypothyroidism, such as skin changes or enlargement of the tongue.[19]

Pregnancy

[edit]

Hypothyroidism when untreated may lead to infertility and an increased risk of miscarriage or infant death around the time of birth, mostly in severe cases of hypothyroidism.[20][21] Women are affected by hypothyroidism in 0.3–0.5% of pregnancies.[22] Subclinical hypothyroidism during pregnancy is associated with birth of the baby before 37 weeks of pregnancy.[23]

Children

[edit]

Newborn children with hypothyroidism may have normal birth weight and height (although the head may be larger than expected and the posterior fontanelle may be open). Some may have drowsiness, decreased muscle tone, poor weight gain, a hoarse-sounding cry, feeding difficulties, constipation, an enlarged tongue, umbilical hernia, dry skin, a decreased body temperature, and jaundice.[24] A goiter is rare, although it may develop later in children who have a thyroid gland that does not produce functioning thyroid hormone.[24] A goiter may also develop in children growing up in areas with iodine deficiency.[25] Normal growth and development may be delayed, and not treating infants may lead to an intellectual impairment (IQ 6–15 points lower in severe cases). Other problems include the following: difficulty with large scale and fine motor skills and coordination, reduced muscle tone, squinting, decreased attention span, and delayed speaking.[24] Tooth eruption may be delayed.[26]

In older children and adolescents, the symptoms of hypothyroidism may include fatigue, cold intolerance, sleepiness, muscle weakness, constipation, a delay in growth, overweight for height, pallor, coarse and thick skin, increased body hair, irregular menstrual cycles in girls, and delayed puberty. Signs may include delayed relaxation of the ankle reflex and a slow heartbeat.[24] A goiter may be present with a completely enlarged thyroid gland;[24] sometimes only part of the thyroid is enlarged and it can be knobby.[27]

Causes

[edit]

Hypothyroidism is caused by inadequate function of the gland itself (primary hypothyroidism), inadequate stimulation by thyroid-stimulating hormone from the pituitary gland (secondary hypothyroidism), or inadequate release of thyrotropin-releasing hormone from the brain's hypothalamus (tertiary hypothyroidism).[8][28] Primary hypothyroidism is about a thousandfold more common than central hypothyroidism.[11] Central hypothyroidism is the name used for secondary and tertiary hypothyroidism since the hypothalamus and pituitary gland are at the center of thyroid hormone control.

Iodine deficiency is the most common cause of primary hypothyroidism and endemic goiter worldwide.[8][9] In areas of the world with sufficient dietary iodine, hypothyroidism is most commonly caused by the autoimmune disease Hashimoto's thyroiditis (chronic autoimmune thyroiditis).[8][9] Hashimoto's may be associated with a goiter. It is characterized by infiltration of the thyroid gland with T lymphocytes and autoantibodies against specific thyroid antigens such as thyroid peroxidase, thyroglobulin and the TSH receptor.[8]

After women give birth, about 5% develop postpartum thyroiditis which can occur up to nine months afterwards.[29] This is characterized by a short period of hyperthyroidism followed by a period of hypothyroidism; 20–40% remain permanently hypothyroid.[29]

Autoimmune thyroiditis (Hashimoto's) is associated with other immune-mediated diseases such as diabetes mellitus type 1, pernicious anemia, myasthenia gravis, celiac disease, rheumatoid arthritis and systemic lupus erythematosus.[8] It may occur as part of autoimmune polyendocrine syndrome (type 1 and type 2).[8]

Iatrogenic hypothyroidism can be surgical (a result of thyroidectomy, usually for thyroid nodules or cancer) or following radioiodine ablation (usually for Graves' disease).

Type of hypothyroidism Causes
Primary hypothyroidism[8] Iodine deficiency (developing countries), autoimmune thyroiditis, subacute granulomatous thyroiditis, subacute lymphocytic thyroiditis, postpartum thyroiditis, previous thyroidectomy, acute infectious thyroiditis,[30] previous radioiodine treatment, previous external beam radiotherapy to the neck
Medication: lithium-based mood stabilizers, amiodarone, interferon alpha, tyrosine kinase inhibitors such as sunitinib
Central hypothyroidism[11] Lesions compressing the pituitary (pituitary adenoma, craniopharyngioma, meningioma, glioma, Rathke's cleft cyst, metastasis, empty sella, aneurysm of the internal carotid artery), surgery or radiation to the pituitary, drugs, injury, vascular disorders (pituitary apoplexy, Sheehan syndrome, subarachnoid hemorrhage), autoimmune diseases (lymphocytic hypophysitis, polyglandular disorders), infiltrative diseases (iron overload due to hemochromatosis or thalassemia, neurosarcoidosis, Langerhans cell histiocytosis), particular inherited congenital disorders, and infections (tuberculosis, mycoses, syphilis)
Congenital hypothyroidism[31] Thyroid dysgenesis (75%), thyroid dyshormonogenesis (20%), maternal antibody or radioiodine transfer
Syndromes: mutations (in GNAS complex locus, PAX8, TTF-1/NKX2-1, TTF-2/FOXE1), Pendred's syndrome (associated with sensorineural hearing loss)
Transiently: due to maternal iodine deficiency or excess, anti-TSH receptor antibodies, certain congenital disorders, neonatal illness
Central: pituitary dysfunction (idiopathic, septo-optic dysplasia, deficiency of PIT1, isolated TSH deficiency)

Pathophysiology

[edit]
Diagram of a person with a large blue arrow representing the actions of thyroxine on the body and a green and red arrow representing actions of TSH and TRH respectively
Diagram of the hypothalamic–pituitary–thyroid axis. The hypothalamus secretes TRH (green), which stimulates the pituitary gland to produce TSH (red). This, in turn, stimulates the production of thyroxine by the thyroid (blue). Thyroxine levels decrease TRH and TSH production by a negative feedback process.

Thyroid hormone is required for the normal functioning of numerous tissues in the body. In healthy individuals, the thyroid gland predominantly secretes thyroxine (T4), which is converted into triiodothyronine (T3) in other organs by the selenium-dependent enzyme iodothyronine deiodinase.[32] Triiodothyronine binds to the thyroid hormone receptor in the nucleus of cells, where it stimulates the turning on of particular genes and the production of specific proteins.[33] Additionally, the hormone binds to integrin αvβ3 on the cell membrane, thereby stimulating the sodium–hydrogen antiporter and processes such as formation of blood vessels and cell growth.[33] In blood, almost all thyroid hormone (99.97%) are bound to plasma proteins such as thyroxine-binding globulin; only the free unbound thyroid hormone is biologically active.[8]

Electrocardiograms are abnormal in both primary overt hypothyroidism and subclinical hypothyroidism.[34] T3 and TSH are essential for the regulation of cardiac electrical activity.[34] Prolonged ventricular repolarization and atrial fibrillation are often seen in hypothyroidism.[34]

The thyroid gland is the only source of thyroid hormone in the body; the process requires iodine and the amino acid tyrosine. The gland takes up iodine in the bloodstream and incorporates it into thyroglobulin molecules. The process is controlled by the thyroid-stimulating hormone (TSH, thyrotropin), which is secreted by the pituitary. Not enough iodine, or not enough TSH, can decrease thyroid hormone production.[28]

The hypothalamic–pituitary–thyroid axis plays a key role in maintaining thyroid hormone levels within normal limits. Production of TSH by the anterior pituitary gland is stimulated in turn by thyrotropin-releasing hormone (TRH), released from the hypothalamus. Production of TSH and TRH is decreased by thyroxine by a negative feedback process. Not enough TRH, which is uncommon, can lead to insufficient TSH release and therefore insufficient thyroid hormone production.[11]

Pregnancy leads to marked changes in thyroid hormone physiology. The gland increases in size by 10%, thyroxine production increases by 50%, and iodine requirements increase. Many women have normal thyroid function but have immunological evidence of thyroid autoimmunity (as evidenced by autoantibodies) or are iodine-deficient, and develop evidence of hypothyroidism before or after giving birth.[35]

Diagnosis

[edit]

Laboratory testing of thyroid stimulating hormone (TSH) levels in the blood is considered the best initial test for hypothyroidism; a second TSH level is often obtained several weeks later for confirmation.[36] Levels may be abnormal in the context of other illnesses, and TSH testing in hospitalized people is discouraged unless thyroid dysfunction is strongly suspected[8] as the cause of the acute illness.[12] An elevated TSH level indicates that the thyroid gland is not producing enough thyroid hormone, and free T4 levels are then often obtained.[8][12][27] Measuring T3 in the assessment for hypothyroidism is discouraged by the American Association of Clinical Endocrinologists (AACE) and National Institute for Health and Care Excellence (NICE).[8] NICE recommends routine T4 testing in children where clinically indicated, and in adults only if central hypothyroidism is suspected or the TSH is abnormal.[12] There are several symptom rating scales for hypothyroidism; they provide a degree of objectivity but have limited use for diagnosis.[8]

TSH T4 Interpretation
Normal Normal Normal thyroid function
Elevated Low Overt hypothyroidism
Normal/low Low Central hypothyroidism
Elevated Normal Subclinical hypothyroidism

Many cases of hypothyroidism are associated with mild elevations in creatine kinase and liver enzymes in the blood. They typically return to normal when hypothyroidism has been fully treated.[8] Levels of cholesterol, low-density lipoprotein and lipoprotein (a) can be elevated;[8] the impact of subclinical hypothyroidism on lipid parameters is less well-defined.[25]

Very severe hypothyroidism and myxedema coma are characteristically associated with low sodium levels in the blood together with elevations in antidiuretic hormone, as well as acute worsening of kidney function due to several causes.[19] For most causes, however, it is unclear if the relationship is causal.[37]

A diagnosis of hypothyroidism without any lumps or masses felt within the thyroid gland does not require thyroid imaging; however, if the thyroid feels abnormal, diagnostic imaging is then recommended.[36] The presence of antibodies against thyroid peroxidase (TPO) makes it more likely that thyroid nodules are caused by autoimmune thyroiditis, but if there is any doubt, a needle biopsy may be required.[8]

Central

[edit]

If the TSH level is normal or low and serum free T4 levels are low, this is suggestive of central hypothyroidism (not enough TSH or TRH secretion by the pituitary gland or hypothalamus, respectively). There may be other features of hypopituitarism, such as menstrual cycle abnormalities and adrenal insufficiency. There might also be symptoms of a pituitary mass such as headaches and vision changes. Central hypothyroidism should be investigated further to determine the underlying cause.[11][36]

Overt

[edit]

In overt primary hypothyroidism, TSH levels are high and T4 levels are low. Overt hypothyroidism may also be diagnosed in those who have a TSH on multiple occasions of greater than 5mIU/L, appropriate symptoms, and only a borderline low T4.[38] It may also be diagnosed in those with a TSH of greater than 10mIU/L.[38]

Subclinical

[edit]

Subclinical hypothyroidism is a biochemical diagnosis characterized by an elevated serum TSH level, but with a normal serum free thyroxine level.[39][40][41] The incidence of subclinical hypothyroidism is estimated to be 3-15% and a higher incidence is seen in elderly people, females and those with lower iodine levels.[39] Subclinical hypothyroidism is most commonly caused by autoimmune thyroid diseases, especially Hashimoto's thyroiditis.[42] The presentation of subclinical hypothyroidism is variable and classic signs and symptoms of hypothyroidism may not be observed.[40] Of people with subclinical hypothyroidism, a proportion will develop overt hypothyroidism each year. In those with detectable antibodies against thyroid peroxidase (TPO), this occurs in 4.3%, while in those with no detectable antibodies, this occurs in 2.6%.[8] In addition to detectable anti-TPO antibodies, other risk factors for conversion from subclinical hypothyroidism to overt hypothyroidism include female sex or in those with higher TSH levels or lower level of normal free T4 levels.[39] Those with subclinical hypothyroidism and detectable anti-TPO antibodies who do not require treatment should have repeat thyroid function tested more frequently (e.g. every 6 months) compared with those who do not have antibodies.[36][39]

Pregnancy

[edit]

During pregnancy, the thyroid gland must produce 50% more thyroid hormone to provide enough thyroid hormone for the developing fetus and the expectant mother.[43] In pregnancy, free thyroxine levels may be lower than anticipated due to increased binding to thyroxine-binding globulin and decreased binding to albumin. They should either be corrected for the stage of pregnancy,[35] or total thyroxine levels should be used instead for diagnosis.[8] TSH values may also be lower than normal (particularly in the first trimester) and the normal range should be adjusted for the stage of pregnancy.[8][35]

In pregnancy, subclinical hypothyroidism is defined as a TSH between 2.5 and 10 mIU/L with a normal thyroxine level, while those with TSH above 10 mIU/L are considered to be overtly hypothyroid even if the thyroxine level is normal.[35] Antibodies against TPO may be important in making treatment decisions, and should, therefore, be determined in women with abnormal thyroid function tests.[8] Determination of TPO antibodies may be considered as part of the assessment of recurrent miscarriage, as subtle thyroid dysfunction can be associated with pregnancy loss,[8] but this recommendation is not universal,[44] and the presence of thyroid antibodies may not predict future outcomes.[45]

Prevention

[edit]
A 3-month-old infant with untreated congenital hypothyroidism showing myxedematous facies, a big tongue, and skin mottling

Hypothyroidism may be prevented in a population by adding iodine to commonly used foods. This public health measure has eliminated endemic childhood hypothyroidism in countries where it was once common. In addition to promoting the consumption of iodine-rich foods such as dairy and fish, many countries with moderate iodine deficiency have implemented universal salt iodization.[46] Encouraged by the World Health Organization,[47] 70% of the world's population across 130 countries are receiving iodized salt. In some countries, iodized salt is added to bread.[46] Despite this, iodine deficiency has reappeared in some Western countries due to attempts to reduce salt intake.[46]

Pregnant and breastfeeding women, who require 66% more daily iodine than non-pregnant women, may still not be getting enough iodine.[46][48] The World Health Organization recommends a daily intake of 250 μg for pregnant and breastfeeding women.[49] As many women will not achieve this from dietary sources alone, the American Thyroid Association recommends a 150 μg daily supplement by mouth.[35][50]

Screening

[edit]

Screening for hypothyroidism is performed in the newborn period in many countries, generally using TSH. This has led to the early identification of many cases and thus the prevention of developmental delay.[51] It is the most widely used newborn screening test worldwide.[52] While TSH-based screening will identify the most common causes, the addition of T4 testing is required to pick up the rarer central causes of neonatal hypothyroidism.[24] If T4 determination is included in the screening done at birth, this will identify cases of congenital hypothyroidism of central origin in 1:16,000 to 1:160,000 children. Considering that these children usually have other pituitary hormone deficiencies, early identification of these cases may prevent complications.[11]

In adults, widespread screening of the general population is debated. Some organizations (such as the United States Preventive Services Task Force) state that evidence is insufficient to support routine screening,[53] while others (such as the American Thyroid Association) recommend either intermittent testing above a certain age in all sexes or only in women.[8] Targeted screening may be appropriate in a number of situations where hypothyroidism is common: other autoimmune diseases, a strong family history of thyroid disease, those who have received radioiodine or other radiation therapy to the neck, those who have previously undergone thyroid surgery, those with an abnormal thyroid examination, those with psychiatric disorders, people taking amiodarone or lithium, and those with a number of health conditions (such as certain heart and skin conditions).[8] Yearly thyroid function tests are recommended in people with Down syndrome, as they are at higher risk of thyroid disease.[54] Guidelines for England and Wales from the National Institute for Health and Care Excellence (NICE) recommend testing for thyroid disease in people with type 1 diabetes and new-onset atrial fibrillation, and suggests testing in those with depression or unexplained anxiety (all ages), in children with abnormal growth, or unexplained change in behavior or school performance.[12] NICE also recommends screening for celiac disease in people with a diagnosis of autoimmune thyroid disease.[55]

Management

[edit]

Hormone replacement

[edit]

Hypothyroidism is managed by hormone substitution with a synthetic long-acting form of thyroxine, known as levothyroxine (L-thyroxine).[8][17] In young and otherwise healthy people with overt hypothyroidism, a full replacement dose (adjusted by weight) can be started immediately; in the elderly and people with heart disease a lower starting dose is recommended to prevent oversupplementation and risk of complications.[8][28][12] Lower doses may be sufficient in those with subclinical hypothyroidism, while people with central hypothyroidism may require a higher-than-average dose.[8]

Blood and TSH levels are monitored to help determine whether the dose is adequate. This is done 4–8 weeks after the start of treatment or a change in levothyroxine dose. Once the adequate replacement dose has been established, the tests can be repeated after 6 and then 12 months, unless there is a change in symptoms.[8] Normalization of TSH does not mean that other abnormalities associated with hypothyroidism improve entirely, such as elevated cholesterol levels.[56]

In people with central hypothyroidism, TSH is not a reliable marker of hormone replacement and decisions are based mainly on the free T4 level.[8][11] Levothyroxine is best taken 30–60 minutes before breakfast, or four hours after food,[8] as certain substances such as food and calcium can inhibit the absorption of levothyroxine.[57] There is no direct way of increasing thyroid hormone secretion by the thyroid gland.[17]

Liothyronine

[edit]

Treatment with liothyronine (synthetic T3) alone has not received enough study to make a recommendation as to its use; due to its shorter half-life it would need to be taken more often than levothyroxine.[8]

Adding liothyronine to levothyroxine has been suggested as a measure to provide better symptom control, but this has not been confirmed by studies.[9][17][58] In 2007, the British Thyroid Association stated that combined T4 and T3 therapy carried a higher rate of side effects and no benefit over T4 alone.[17][59] Similarly, American guidelines discourage combination therapy due to a lack of evidence, although they acknowledge that some people feel better when receiving combination therapy.[8] Guidelines by National Institute for Health and Care Excellence (NICE) discourage liothyronine.[12]

People with hypothyroidism who do not feel well despite optimal levothyroxine dosing may request adjunctive treatment with liothyronine. A 2012 guideline from the European Thyroid Association recommends that support should be offered concerning the chronic nature of the disease and that other causes of the symptoms should be excluded. The addition of liothyronine should be regarded as experimental, initially only for a trial period of 3 months, and in a set ratio to the current dose of levothyroxine.[60] The guideline explicitly aims to enhance the safety of this approach and to counter its indiscriminate use.[60] A 2014 guideline from the American Thyroid Association recommends against the use of liothyronine.[61]

Desiccated animal thyroid

[edit]

Desiccated thyroid extract is an animal-based thyroid gland extract,[17] most commonly from pigs. It is a combination therapy, containing forms of T4 and T3.[17] It also contains calcitonin (a hormone produced in the thyroid gland involved in the regulation of calcium levels), T1 and T2; these are not present in synthetic hormone medication.[62] This extract was once a mainstream hypothyroidism treatment, but has been disregarded since the 1970s and its use is unsupported by evidence;[9][17] British Thyroid Association and American professional guidelines discourage its use,[8][59][61] as does NICE.[12]

Subclinical hypothyroidism

[edit]

There is no evidence of a benefit from treating subclinical hypothyroidism in those who are not pregnant, and there are potential risks of unnecessary overtreatment.[63] Untreated subclinical hypothyroidism may be associated with a modest increase in the risk of coronary artery disease when the TSH is over 10 mIU/L.[63][64] There may be an increased risk for cardiovascular death.[65] A 2007 review found no benefit of thyroid hormone replacement except for "some parameters of lipid profiles and left ventricular function".[66] There is no association between subclinical hypothyroidism and an increased risk of bone fractures,[67] nor is there a link with cognitive decline.[68]

American guidelines recommend that treatment should be considered in people with symptoms of hypothyroidism, detectable antibodies against thyroid peroxidase, a history of heart disease, or are at an increased risk for heart disease if the TSH is elevated but below 10 mIU/L.[8] American guidelines further recommend universal treatment (independent of risk factors) in those with TSH levels that are markedly elevated; above 10 mIU/L because of an increased risk of heart failure or death due to cardiovascular disease.[8][39] NICE recommends that those with a TSH above 10 mIU/L should be treated in the same way as overt hypothyroidism. Those with an elevated TSH but below 10 mIU/L who have symptoms suggestive of hypothyroidism should have a trial of treatment but intend to stop this if the symptoms persist despite normalization of the TSH.[12]

Myxedema coma

[edit]

Myxedema coma or severe decompensated hypothyroidism usually requires admission to the intensive care unit, close observation and treatment of abnormalities in breathing, temperature control, blood pressure, and sodium levels. Mechanical ventilation may be required, as well as fluid replacement, vasopressor agents, careful rewarming, and corticosteroids (for possible adrenal insufficiency which can occur together with hypothyroidism). Careful correction of low sodium levels may be achieved with hypertonic saline solutions or vasopressin receptor antagonists.[19] For rapid treatment of hypothyroidism, levothyroxine or liothyronine may be administered intravenously, particularly if the level of consciousness is too low to be able to safely swallow medication.[19] While administration through a nasogastric tube is possible, this may be unsafe and is discouraged.[19]

Pregnancy

[edit]

In women with known hypothyroidism who become pregnant, it is recommended that serum TSH levels are closely monitored. Levothyroxine should be used to keep TSH levels within the normal range for that trimester. The first-trimester normal range is below 2.5 mIU/L and the second and third trimesters normal range is below 3.0 mIU/L.[17][35] Measurement of free T4 in pregnancy is not recommended due to changes in levels of serum protein binding. Similarly to TSH, the thyroxine results should be interpreted according to the appropriate reference range for that stage of pregnancy.[8] The levothyroxine dose often needs to be increased after pregnancy is confirmed,[8][28][35] although this is based on limited evidence and some recommend that it is not always required; decisions may need to based on TSH levels.[69]

Women with anti-TPO antibodies who are trying to become pregnant (naturally or by assisted means) may require thyroid hormone supplementation even if the TSH level is normal. This is particularly true if they have had previous miscarriages or have been hypothyroid in the past.[8] Supplementary levothyroxine may reduce the risk of preterm birth and possibly miscarriage.[70] The recommendation is stronger in pregnant women with subclinical hypothyroidism (defined as TSH 2.5–10 mIU/L) who are anti-TPO positive, in view of the risk of overt hypothyroidism. If a decision is made not to treat, close monitoring of the thyroid function (every 4 weeks in the first 20 weeks of pregnancy) is recommended.[8][35] If anti-TPO is not positive, treatment for subclinical hypothyroidism is not currently recommended.[35] It has been suggested that many of the aforementioned recommendations could lead to unnecessary treatment, in the sense that the TSH cutoff levels may be too restrictive in some ethnic groups; there may be little benefit from treatment of subclinical hypothyroidism in certain cases.[69] Treatment for subclinical hypothyroidism in pregnancy is not conclusively shown to decrease the incidence of miscarriage.[71][72][73]

Alternative medicine

[edit]

The effectiveness and safety of using Chinese herbal medicines to treat hypothyroidism is not known.[74]

Epidemiology

[edit]

Hypothyroidism is the most frequent endocrine disorder.[34] Worldwide about one billion people are estimated to be iodine deficient; however, it is unknown how often this results in hypothyroidism.[13] In large population-based studies in Western countries with sufficient dietary iodine, 0.3–0.4% of the population have overt hypothyroidism. A larger proportion, 4.3–8.5%, have subclinical hypothyroidism.[8] Undiagnosed hypothyroidism is estimated to affect about 4–7% of community-derived populations in the US and Europe.[75] Of people with subclinical hypothyroidism, 80% have a TSH level below the 10 mIU/L mark regarded as the threshold for treatment.[41] Children with subclinical hypothyroidism often return to normal thyroid function, and a small proportion develops overt hypothyroidism (as predicted by evolving antibody and TSH levels, the presence of celiac disease, and the presence of a goiter).[76]

Women are more likely to develop hypothyroidism than men. In population-based studies, women were seven times more likely than men to have TSH levels above 10 mU/L.[8] 2–4% of people with subclinical hypothyroidism will progress to overt hypothyroidism each year. The risk is higher in those with antibodies against thyroid peroxidase.[8][41] Subclinical hypothyroidism is estimated to affect approximately 2% of children; in adults, subclinical hypothyroidism is more common in the elderly, and in White people.[40] There is a much higher rate of thyroid disorders, the most common of which is hypothyroidism, in individuals with Down syndrome[24][54] and Turner syndrome.[24]

Very severe hypothyroidism and myxedema coma are rare, with it estimated to occur in 0.22 per million people a year.[19] The majority of cases occur in women over 60 years of age, although it may happen in all age groups.[19]

Most hypothyroidism is primary in nature. Central/secondary hypothyroidism affects 1:20,000 to 1:80,000 of the population or about one out of every thousand people with hypothyroidism.[11]

History

[edit]

In 1811, Bernard Courtois discovered iodine was present in seaweed, and iodine intake was linked with goiter size in 1820 by Jean-Francois Coindet.[77] Gaspard Adolphe Chatin proposed in 1852 that endemic goiter was the result of not enough iodine intake, and Eugen Baumann demonstrated iodine in thyroid tissue in 1896.[77]

The first cases of myxedema were recognized in the mid-19th century (the 1870s), but its connection to the thyroid was not discovered until the 1880s when myxedema was observed in people following the removal of the thyroid gland (thyroidectomy).[78] The link was further confirmed in the late 19th century when people and animals who had had their thyroid removed showed improvement in symptoms with transplantation of animal thyroid tissue.[9] The severity of myxedema, and its associated risk of mortality and complications, created interest in discovering effective treatments for hypothyroidism.[78] Transplantation of thyroid tissue demonstrated some efficacy, but recurrences of hypothyroidism was relatively common, and sometimes required multiple repeat transplantations of thyroid tissue.[78]

In 1891, the English physician George Redmayne Murray introduced subcutaneously injected sheep thyroid extract,[79] followed shortly after by an oral formulation.[9][80] Purified thyroxine was introduced in 1914 and in the 1930s synthetic thyroxine became available, although desiccated animal thyroid extract remained widely used. Liothyronine was identified in 1952.[9]

Early attempts at titrating therapy for hypothyroidism proved difficult. After hypothyroidism was found to cause a lower basal metabolic rate, this was used as a marker to guide adjustments in therapy in the early 20th century (around 1915).[78] However, a low basal metabolic rate was known to be non-specific, also present in malnutrition.[78] The first laboratory test to help assess thyroid status was the serum protein-bound iodine, which came into use around the 1950s.

In 1971, the thyroid stimulating hormone (TSH) radioimmunoassay was developed, which was the most specific marker for assessing thyroid status in patients.[78] Many people who were being treated based on basal metabolic rate, minimizing hypothyroid symptoms, or based on serum protein-bound iodine, were found to have excessive thyroid hormone.[78] The following year, in 1972, a T3 radioimmunoassay was developed, and in 1974, a T4 radioimmunoassay was developed.[78]

Other animals

[edit]
Photograph of a Labrador Retriever dog with sagging facial skin characteristic of hypothyroidism
Characteristic changes in the facial skin of a Labrador Retriever with hypothyroidism

In veterinary practice, dogs are the species most commonly affected by hypothyroidism. The majority of cases occur as a result of primary hypothyroidism, of which two types are recognized: lymphocytic thyroiditis, which is probably immune-driven and leads to destruction and fibrosis of the thyroid gland, and idiopathic atrophy, which leads to the gradual replacement of the gland by fatty tissue.[14][81] There is often lethargy, cold intolerance, exercise intolerance, and weight gain. Skin changes and fertility problems are seen in dogs with hypothyroidism, as well as many other symptoms.[81] The signs of myxedema can be seen in dogs, with prominence of skin folds on the forehead, and cases of myxedema coma are encountered.[14] The diagnosis can be confirmed by a blood test, as the clinical impression alone may lead to overdiagnosis.[14][81] Lymphocytic thyroiditis is associated with detectable antibodies against thyroglobulin, although they typically become undetectable in advanced disease.[81] Treatment is with thyroid hormone replacement.[14]

Other species that are less commonly affected include cats and horses, as well as other large domestic animals. In cats, hypothyroidism is usually the result of other medical treatments such as surgery or radiation. In young horses, congenital hypothyroidism has been reported predominantly in Western Canada and has been linked with the mother's diet.[14]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
Hypothyroidism, also known as underactive , is a condition in which the gland—a small, butterfly-shaped located in the front of the neck—fails to produce sufficient amounts of , primarily thyroxine (T4) and (T3), which are essential for regulating , energy levels, and numerous bodily functions. This hormonal deficiency slows down nearly every organ system, potentially leading to a wide range of symptoms and complications if left untreated, including fatigue, weight gain, and increased risk of heart disease. The condition affects approximately 10% of Americans aged 12 years and older, with prevalence increasing with age and recent data showing about 11.7% by 2019; it is up to eight times more common in women than in men, particularly those over 60 or with autoimmune predispositions. The most frequent cause is , an autoimmune disorder where the attacks the thyroid gland, leading to and gradual hormone production decline; other causes include thyroid surgery or , certain medications like or , congenital defects, (rare in iodine-sufficient regions), and secondary issues from disorders. Symptoms often develop slowly over months or years and can include general cold intolerance, , dry skin, thinning hair, , depression, slowed heart rate, and in severe cases, coma—a life-threatening emergency characterized by extreme lethargy and . In infants, undiagnosed can cause developmental delays, poor feeding, and prolonged , underscoring the importance of programs. Diagnosis typically involves blood tests measuring levels of (TSH) from the and free T4; elevated TSH with low T4 confirms primary hypothyroidism, while normal or low TSH suggests secondary causes. Treatment is straightforward and highly effective, consisting of lifelong oral replacement with synthetic (T4), which normalizes hormone levels and alleviates symptoms in nearly all patients when dosed appropriately through regular monitoring. With proper management, individuals with hypothyroidism can lead normal, healthy lives, though untreated cases may contribute to complications such as high , , or goiter formation.

Overview

Definition

Hypothyroidism is a medical condition characterized by insufficient production of , primarily thyroxine (T4) and (T3), by the . This underactive state leads to a slowdown in the body's metabolic processes, affecting energy utilization and overall physiological function. The , located in the neck, normally synthesizes these hormones through iodination of residues in , a process regulated by (TSH) from the . Thyroid hormones play a critical role in regulating basal metabolic rate, which governs the consumption of oxygen and production of heat in cells throughout the body. They are essential for promoting growth and development, particularly during fetal and early childhood stages, by influencing cell differentiation, proliferation, and maturation in various tissues. Additionally, T3 and T4 support organ function, including cardiovascular, nervous, and musculoskeletal systems, ensuring normal homeostasis in adults. In contrast to , where the overproduces leading to accelerated , hypothyroidism results in deficiency and metabolic deceleration. Euthyroid states represent normal function with balanced levels. Hypothyroidism can manifest as congenital, present at birth due to developmental defects, or acquired later in life from various insults to the .

Classification

Hypothyroidism is classified primarily based on its etiology, distinguishing between dysfunction originating in the thyroid gland itself and issues arising from the central regulation of thyroid hormone production. Primary hypothyroidism results from failure of the thyroid gland to produce sufficient thyroid hormones, often due to autoimmune destruction as seen in , the most common cause in iodine-sufficient regions. In contrast, central hypothyroidism encompasses secondary forms caused by insufficiency, leading to inadequate (TSH) secretion, and tertiary forms stemming from hypothalamic dysfunction that impairs (TRH) production. The condition is further subdivided by severity and biochemical profile, with overt hypothyroidism defined by elevated TSH levels alongside low free thyroxine (T4) concentrations, typically resulting in noticeable clinical symptoms. Subclinical hypothyroidism, a milder variant, features elevated TSH with normal T4 levels and is often or presents with subtle manifestations. Severity can be graded as mild (corresponding to subclinical cases), moderate (overt hypothyroidism with TSH often exceeding 10 mU/L), and severe (progressing to myxedema coma, a life-threatening involving , altered mental status, and multiorgan failure). Hypothyroidism is also categorized temporally as congenital, present at birth due to factors such as thyroid dysgenesis or maternal , which requires early screening to prevent developmental delays, or acquired, developing later in life from causes like , surgical intervention, or . These classifications provide a framework for understanding the diverse presentations and guide appropriate management strategies.

Clinical Presentation

Signs and Symptoms in Adults

Hypothyroidism in adults often presents with a gradual onset of nonspecific symptoms that can mimic other conditions, making early recognition challenging. Common symptoms include , which may manifest as hypersomnia, affects daily functioning, is reported in the majority of cases, and can occur even in subclinical hypothyroidism, contributing to stress intolerance and slower recovery from illness. Persistent fatigue is a primary and often debilitating symptom of hypothyroidism. It is frequently exacerbated by concurrent deficiencies in vitamin D and vitamin B12, which are common in patients with autoimmune thyroid disease. Studies have reported vitamin B12 deficiency in approximately 46% of patients with autoimmune hypothyroidism, while vitamin D deficiency has been observed in up to 96% in some cohorts. These deficiencies share overlapping symptoms with hypothyroidism, including fatigue, weakness, depression, and cognitive impairment, and can worsen persistent symptoms. Screening for these deficiencies is often recommended in hypothyroid patients. Patients also experience unexplained despite often reduced appetite and no significant changes in diet or activity levels. Patients frequently experience cold intolerance, which is typically a generalized increased sensitivity to cold even in warm environments comfortable to others, due to slowed metabolism and reduced thermogenesis from thyroid hormone deficiency. Cold intolerance is generally systemic rather than localized; a specific intense chilling sensation confined to the head is not described as a typical symptom in major medical sources. Patients also experience due to slowed gastrointestinal motility. Dry skin and , including thinning of the outer eyebrows, are dermatological manifestations, while menstrual irregularities such as heavier or irregular periods occur in women of reproductive age. Depression, anxiety, occasional obsessions, and cognitive issues, like problems and occasional headaches, further contribute to the emotional and mental burden. Physical signs are equally indicative and include (low heart rate), diastolic hypertension (particularly elevated diastolic pressure due to increased vascular resistance), although hypotension may occur in severe cases, a slowed that reflects reduced metabolic demands, and goiter, an enlarged palpable in the . Delayed relaxation of deep tendon reflexes, particularly noticeable in the ankles, is a classic neurological sign stemming from diminished muscle responsiveness; headaches are occasionally reported and rarely associated with increased intracranial pressure. Hoarseness arises from vocal cord , and periorbital contributes to a puffy facial appearance. Patients may also experience a sensation of excessive mucus in the throat (often described as a "phlegmy" or "verschleimter Hals"), which can be linked to hoarseness, swallowing difficulties, or sinus/nasal congestion from fluid retention, myxedematous changes, edema, and hypertrophy of mucous glands in the upper airways. Hypothyroidism may also be associated with nasal congestion or obstruction resembling nonallergic rhinitis, attributed to myxedematous changes such as fluid retention, edema in nasal tissues, hypertrophy of mucous glands, and accumulation of glycosaminoglycans leading to swelling; these nasal symptoms often improve with levothyroxine treatment. Additionally, hypothyroidism is associated with obstructive sleep apnea, which can contribute to breathing difficulties, including positional worsening due to upper airway obstruction from myxedema-related tissue swelling. The condition's progression is typically insidious, with symptoms evolving over months to years from subtle complaints like mild to more pronounced effects as thyroid hormone levels decline further. Systemically, hypothyroidism impacts the cardiovascular system by causing dyslipidemia characterized by elevated (LDL) cholesterol and triglyceride levels, frequently with normal high-density lipoprotein (HDL) cholesterol levels, increasing the risk of and heart disease. These cardiovascular manifestations and lipid abnormalities are commonly associated with hypothyroidism but are nonspecific and not definitive for diagnosis; thyroid function tests (e.g., TSH and free T4) are required for confirmation. Musculoskeletal involvement manifests as myalgias, including muscle aches, tenderness, stiffness, weakness, and joint pain (which may include lower back pain), which can limit mobility. Bladder pressure and frequent urination are not typical symptoms of hypothyroidism; however, some evidence links hypothyroidism to urinary retention or reduced voiding rather than increased frequency. Cognitively, it exacerbates depressive symptoms and impairs memory and concentration, potentially leading to in severe cases. In rare untreated instances, symptoms can culminate in myxedema coma, a life-threatening characterized by profound and .

Effects in Pregnancy

During pregnancy, the demand for thyroid hormones increases by approximately 50% due to physiological adaptations such as elevated renal clearance of iodide and stimulation of the thyroid gland by human chorionic gonadotropin (hCG), which can unmask subclinical hypothyroidism in susceptible women. This heightened requirement, combined with the placenta's role in metabolizing maternal thyroxine (T4), places additional stress on thyroid function, potentially leading to overt hypothyroidism if iodine intake is marginal or preexisting thyroid autoimmunity is present. Maternal hypothyroidism is associated with several adverse outcomes, including an increased risk of , , and postpartum hemorrhage. Untreated overt hypothyroidism elevates the odds of through mechanisms involving and , while may arise from impaired due to thyroid hormone deficiency. Postpartum hemorrhage risk is heightened, particularly in cases of severe hypothyroidism, due to reduced uterine contractility and . Fetal risks from maternal hypothyroidism include neurodevelopmental delays, , higher rates of , and . Insufficient transplacental transfer of maternal T4 in early can impair fetal brain development, leading to decrements in IQ and psychomotor skills, as evidenced by cohort studies showing persistent cognitive deficits in offspring. and preterm delivery are common, often linked to or , while and rates increase significantly in untreated cases, with odds ratios up to 2-4 times higher compared to euthyroid pregnancies. Symptoms of hypothyroidism during often overlap with normal gestational changes, such as and , which can delay recognition, but specific indicators like persistent , beyond typical levels, or cold intolerance may prompt further evaluation. These overlaps underscore the importance of routine screening, as diagnosis relies on laboratory tests detailed elsewhere.

Manifestations in Children

Hypothyroidism in children presents with age-specific manifestations that differ from those in adults, primarily affecting growth, development, and metabolism. In neonates and infants with , common signs include prolonged , (poor muscle tone), large fontanelles (soft spots on the ), and . Additional features may involve feeding difficulties, such as poor sucking or episodes, , hoarse cry, puffy face, (enlarged tongue), and dry skin. These subtle signs can be overlooked without , which enables early detection and intervention to prevent severe outcomes. If remains untreated, it leads to cretinism, characterized by profound , stunted physical growth, and developmental delays in motor skills and cognition. In older infants, manifestations may include , , and delayed bone maturation, such as absent epiphyses in the knees on radiographs. Acquired hypothyroidism, which develops after the neonatal period, often manifests as growth retardation and due to slowed linear growth velocity. Other symptoms include , , cold intolerance, dry skin, brittle hair, and or aches. In school-age children, poor school performance may arise from concentration difficulties and sluggishness, while dental development is delayed, leading to late eruption of . Adolescents commonly experience , with girls showing amenorrhea or irregular menses and boys exhibiting underdeveloped secondary sexual characteristics. Age-related differences are notable: infants primarily show feeding issues and constipation alongside , whereas school-age children exhibit prominent and impacting daily activities. In severe or prolonged cases across pediatric ages, manifestations can include relative despite poor , goiter, and rare syndromes like Kocher-Debre-Semelaigne, featuring muscular and pseudohypertrophy. Long-term effects of untreated hypothyroidism in children encompass delayed bone maturation, resulting in persistent and skeletal abnormalities, as well as impaired development with risks of subtle cognitive deficits even after treatment initiation. Early thyroid hormone replacement mitigates these risks, but delays can lead to irreversible growth failure and neurodevelopmental issues.

Myxedema Coma

Myxedema coma represents a rare and life-threatening decompensation of severe, long-standing hypothyroidism, characterized by profound metabolic and multisystem dysfunction that requires immediate intensive care intervention. This endocrine emergency typically occurs in patients with inadequately treated or undiagnosed hypothyroidism, leading to critically low levels of thyroid hormones and elevated thyroid-stimulating hormone. It manifests as a hypometabolic state with hallmark features including hypothermia, altered mental status ranging from lethargy to coma, hypotension, hyponatremia, bradycardia, and hypoglycemia, often progressing rapidly to multiorgan failure if untreated. The condition predominantly affects older adults, particularly women over 60 years, with an estimated incidence of approximately 0.12 cases per million population annually. Common precipitants in susceptible hypothyroid patients include infections such as or urinary tract infections, exposure to cold environments, surgical procedures, and administration of sedatives, anesthetics, or other drugs that depress function. Other triggers encompass trauma, cerebrovascular events, congestive , and abrupt discontinuation of hormone replacement therapy, with these factors often unmasking the underlying deficiency in winter months when incidence peaks. In over 77% of cases, such stressors precipitate the coma in individuals with preexisting primary hypothyroidism, which accounts for more than 95% of occurrences. Pathognomonic clinical signs include non-pitting edema known as , resulting in doughy, swollen skin, particularly around the eyes and extremities, alongside serous effusions such as pericardial or pleural accumulations that contribute to hemodynamic instability. is frequent, stemming from , diaphragmatic , or upper airway obstruction due to myxedema-related swelling, including macroglossia and laryngeal edema. Additional features encompass seizures, , and fluid retention, with present in about 72% of patients, in 66%, and altered mental status in nearly 89%. These signs underscore the rapid deterioration and multisystem involvement unique to this extreme hypothyroid state. Despite advances in recognition and management, myxedema coma carries a high of approximately 39%, ranging up to 60% in severe cases, primarily due to shock, multiple organ failure, and delays in . Even with prompt supportive care, outcomes remain poor, influenced by patient age, comorbidities, and the presence of precipitants, highlighting its status as one of the most lethal endocrine emergencies.

Etiology

Primary Hypothyroidism

Primary hypothyroidism refers to thyroid gland dysfunction that directly impairs the synthesis and secretion of , independent of pituitary or hypothalamic regulation. This condition accounts for the majority of hypothyroidism cases and arises from various intrinsic thyroid pathologies. In iodine-sufficient areas, autoimmune destruction dominates, while prevails globally in resource-limited regions. The most common cause in developed countries is autoimmune , with being the predominant form, characterized by lymphocytic infiltration and progressive glandular leading to reduced hormone output. This disorder affects women up to seven times more frequently than men and often coexists with other autoimmune conditions like or celiac disease. Atrophic thyroiditis, a variant of autoimmune , involves chronic inflammation resulting in thyroid atrophy and dense without prominent goiter, further contributing to hormone deficiency. Iodine deficiency stands as the primary global etiology, particularly in developing regions where soil and dietary iodine levels are low, leading to impaired thyroid hormone synthesis and endemic goiter. This preventable cause affects millions, though public health measures like iodized salt have significantly reduced its incidence in many areas. Iatrogenic factors frequently result from therapeutic interventions targeting thyroid or adjacent structures. , the surgical removal of all or part of the gland for conditions such as cancer or multinodular goiter, inevitably causes hypothyroidism requiring hormone replacement. Radioactive iodine ablation, commonly used for like or thyroid malignancy, destroys functional thyroid tissue and induces permanent hypothyroidism in 80% to 90% of patients within 8 to 20 weeks. Similarly, external to the head or neck, often for lymphomas or other cancers, damages thyroid follicles and elevates hypothyroidism risk over time. Drug-induced hypothyroidism occurs when medications interfere with thyroid hormone production or release, particularly in susceptible individuals. Lithium, a mainstay in bipolar disorder treatment, inhibits thyroid hormone secretion and can precipitate hypothyroidism in up to 20% of long-term users. Amiodarone, an iodine-rich antiarrhythmic agent, disrupts hormone synthesis through excess iodine load or direct toxicity, affecting 5% to 20% of recipients. Interferon-alpha, used in hepatitis or malignancy therapy, may trigger autoimmune thyroiditis or directly suppress glandular function. Infiltrative disorders, though uncommon, involve pathological deposits that compromise thyroid architecture. Amyloidosis leads to amyloid protein accumulation within the gland, impairing hormone production, while sarcoidosis causes granulomatous infiltration that disrupts follicular cells and vascular supply. These rare etiologies often manifest in the context of and require targeted management of the underlying condition.

Central Hypothyroidism

Central hypothyroidism arises from dysfunction in the hypothalamic-pituitary-thyroid axis, specifically involving the (secondary hypothyroidism) or the (tertiary hypothyroidism), leading to inadequate stimulation of the gland despite its intrinsic normalcy. Unlike primary forms, central hypothyroidism is characterized by low or inappropriately normal (TSH) levels in the presence of low free thyroxine (FT4). Secondary central hypothyroidism results primarily from pituitary gland disorders that impair TSH production or secretion. Common causes include pituitary adenomas, which are benign tumors that can compress normal pituitary tissue, and craniopharyngiomas, often seen in children and arising from remnants of Rathke's pouch. Sheehan's syndrome, a postpartum pituitary necrosis due to severe hemorrhage and hypovolemic shock, leads to panhypopituitarism including TSH deficiency. Traumatic brain injury or pituitary surgery can also damage the pituitary, resulting in secondary hypothyroidism. Tertiary central hypothyroidism stems from hypothalamic dysfunction, reducing (TRH) production or release, which in turn diminishes pituitary TSH secretion. Hypothalamic tumors, such as gliomas or hamartomas, can disrupt this axis, as can infiltrative diseases like or . Rare genetic mutations contribute, including defects in the TSH-beta gene (TSHB), causing isolated TSH deficiency and congenital nongoitrous hypothyroidism, and mutations in the TRH gene or its receptor (TRHR), leading to TRH deficiency or resistance. Central hypothyroidism frequently occurs within the broader context of , where multiple pituitary hormones are deficient, increasing risks for associated conditions such as from (ACTH) shortfall and due to (FSH/LH) deficiencies. can precipitate life-threatening crises if thyroid replacement is initiated without concurrent support. Recent advances emphasize genetic etiologies, particularly in congenital cases, with mutations in the gene being the most of multiple pituitary hormone deficiency (MPHD), often presenting with central hypothyroidism alongside and deficits. The 2018 European Thyroid Association (ETA) guidelines highlight the role of molecular diagnosis in identifying such mutations to guide targeted management.

Pathophysiology

Thyroid Hormone Synthesis and Regulation

Thyroid hormone synthesis occurs primarily in the follicular cells of the gland. , obtained from dietary sources, is actively transported into thyrocytes via the sodium- symporter (NIS) located on the basolateral , achieving intracellular concentrations 20 to 50 times higher than in plasma; this process is energy-dependent and stimulated by (TSH). Once inside the cell, diffuses to the apical and is oxidized to reactive iodine by (TPO) in the presence of (H₂O₂) generated by dual oxidases (DUOX). The oxidized iodine then iodinates tyrosine residues on (Tg), a large stored in the follicular lumen, forming monoiodotyrosine (MIT) and diiodotyrosine (DIT). TPO subsequently catalyzes the coupling of these iodotyrosines: two DIT molecules couple to form thyroxine (T4), while one DIT and one MIT couple to form (T3). The iodinated Tg is endocytosed, proteolytically cleaved by lysosomal enzymes such as cathepsins to release T4 and T3, and the hormones are secreted into the bloodstream; MIT and DIT are deiodinated intracellularly for iodine recycling. In euthyroid adults, the thyroid gland produces approximately 94–110 μg of T4 and 4–8 μg of T3 daily. Regulation of thyroid hormone production is governed by the hypothalamic-pituitary-thyroid (HPT) axis. (TRH) is secreted by neurons in the paraventricular nucleus of the and travels via the to stimulate the gland to release TSH. TSH binds to G-protein-coupled receptors on follicular cells, activating adenylate cyclase and the pathway, which upregulates NIS expression, TPO activity, and Tg synthesis to promote uptake, organification, and release. Circulating free T3 and T4 exert on the and pituitary, inhibiting TRH and TSH to maintain ; this feedback primarily targets free levels rather than total concentrations. Although the thyroid secretes mostly T4 (about 80% of output) with smaller amounts of T3, the biologically active form T3 is predominantly generated peripherally through deiodination of T4. This conversion occurs via outer-ring deiodination (ORD) catalyzed by type 1 (D1), which is expressed in high-blood-flow tissues like the liver and kidneys and contributes to circulating T3 levels, and type 2 deiodinase (D2), found in the , pituitary, , and , which locally regulates tissue-specific T3 availability. Approximately 80% of daily T3 production (~50 nmol) arises from this peripheral pathway, with D1 and D2 accounting for the ORD reaction that removes an iodine atom from the outer ring of T4. In circulation, thyroid hormones are transported bound to plasma proteins to prevent rapid clearance and ensure steady delivery to tissues. (TBG), synthesized in the liver, is the primary carrier, binding about 75% of serum T4 and a similar proportion of T3 with high affinity (association constant of 1 × 10¹⁰ M⁻¹ for T4). and serve as secondary binders, transporting the remainder, while only 0.03% of T4 and 0.3% of T3 circulate in their free, biologically active forms. TBG's is approximately 5 days, and its concentration (1.1–2.1 mg/dL) supports a large extrathyroidal hormone pool, buffering daily fluctuations in .

Consequences of Hormone Deficiency

Hypothyroidism leads to a profound metabolic slowdown primarily through the deficiency of , which are essential regulators of energy expenditure. The decreases by approximately 30-40% in overt hypothyroidism due to reduced mitochondrial activity and impaired expression of genes involved in . This hypometabolic state manifests as diminished , where thyroid hormone normally activates uncoupling proteins in to generate heat; in its absence, heat production is curtailed, contributing to generalized cold intolerance—an increased sensitivity to cold temperatures affecting the entire body—rather than localized sensations such as intense chilling confined to the head, which is not a characteristic manifestation of hypothyroidism according to standard medical literature. Furthermore, is disrupted, with slowed clearance and increased hepatic synthesis leading to accumulation of in tissues, including the liver, exacerbating . In the cardiovascular system, thyroid hormone deficiency impairs myocardial function by downregulating sarcomeric proteins and calcium-handling genes, resulting in decreased cardiac contractility and . This reduction in is compounded by increased systemic due to and heightened sensitivity to catecholamines, promoting diastolic while systolic pressure remains relatively preserved. Lipid abnormalities further contribute, as hypothyroidism elevates (LDL) cholesterol levels through decreased activity in the liver and reduced clearance from circulation, fostering and endothelial damage. These hemodynamic and metabolic changes collectively heighten the risk of ischemic heart disease. Neurologically, the lack of thyroid hormones affects brain metabolism and structure, leading to via reduced cerebral glucose utilization and altered synthesis, such as decreased serotonin and activity in key regions like the hippocampus. Chronic deficiency can also promote demyelination in peripheral nerves through impaired function and , resulting in neuropathy characterized by slowed nerve conduction. In severe cases, prolonged hypothyroidism overwhelms adaptive mechanisms, culminating in , where profound , , and arise from multisystem failure, including respiratory depression and cardiovascular collapse. In , hormone deficiency impairs growth and development, leading to delayed linear growth and bone maturation due to reduced proliferation in growth plates, as well as neurocognitive deficits from disrupted neuronal migration, myelination, and in the developing . Emerging research highlights genetic factors influencing the severity of hormone deficiency consequences, particularly polymorphisms in genes like DIO2. The Thr92Ala variant in DIO2, for instance, reduces the enzyme's efficiency in converting thyroxine to active at the tissue level, leading to suboptimal local thyroid hormone action and more persistent symptoms such as and cognitive deficits even in euthyroid states. Studies from 2023-2025 indicate that such polymorphisms may explain inter-individual variability in symptom severity among hypothyroid patients on standard therapy. These findings underscore the role of in tailoring treatment to mitigate deficiency impacts.

Diagnostic Evaluation

Laboratory Tests

The diagnosis of hypothyroidism relies primarily on blood tests measuring (TSH) and free thyroxine (FT4) levels, which provide confirmation of thyroid hormone deficiency. TSH serves as the first-line screening test, with elevated levels (>4.5 mU/L) indicating primary hypothyroidism due to thyroid gland failure, while low or inappropriately normal TSH alongside low FT4 suggests central hypothyroidism from pituitary or hypothalamic dysfunction. In overt hypothyroidism, FT4 levels are low, confirming the when paired with elevated TSH; in subclinical hypothyroidism, FT4 remains normal despite elevated TSH. Additional tests include measurement of anti-thyroid peroxidase (anti-TPO) antibodies to identify autoimmune etiology, such as , which is present in most cases of primary hypothyroidism. Serum thyroglobulin (Tg) levels may also be elevated in autoimmune hypothyroidism due to inflammation and destruction of thyroid follicular cells, typically occurring alongside elevated TSH and low FT4 (in overt cases) or normal FT4 (in subclinical cases). Total (T3) levels are rarely needed for initial diagnosis but may be assessed if there is suspicion of impaired peripheral conversion of T4 to T3. Reference ranges for TSH and FT4 are method-specific and should be adjusted for age, sex, and ; for example, TSH upper limits may increase slightly with age (e.g., up to 7 mU/L in those over 70) and are trimester-specific during (e.g., <2.5 mU/L in the first trimester). Common pitfalls in interpretation include non-thyroidal illness syndrome (), where acute or chronic illness can suppress TSH and alter FT4 levels without true thyroid dysfunction, necessitating repeat testing after recovery. supplements can also interfere with results, leading to falsely low TSH or high FT4 readings. Updated 2024 reviews emphasize the combined use of TSH and FT4 assays for accurate , incorporating population-specific intervals to improve precision across diverse groups.

Clinical and Imaging Assessment

The clinical assessment of hypothyroidism begins with a thorough to identify risk factors and symptom chronology. Patients should be queried about history of thyroid disorders, as autoimmune thyroiditis, the most common cause, has a genetic predisposition. Exposure to neck or head radiation, such as from prior cancer therapy, increases the risk of thyroid damage leading to hypothyroidism. Certain medications, including lithium, amiodarone, and immune checkpoint inhibitors, can impair thyroid function and should be documented. The duration and progression of symptoms, such as fatigue, weight gain, cold intolerance, constipation, dry skin, hair loss, and menstrual irregularities, help gauge severity and guide urgency of evaluation. Physical examination focuses on identifying characteristic signs that support the history. of the gland is essential to detect goiter, which may present as diffuse enlargement in autoimmune cases or nodular in or multinodular goiter; a firm, irregular texture suggests . Reflexes, particularly the ankle jerk, often show delayed relaxation phase due to slowed . Skin changes include dryness, coolness, and , while hair may appear coarse, brittle, and thinning, especially in the outer third of the eyebrows. Additional findings like periorbital , hoarse voice, and contribute to the overall picture. These signs, though nonspecific, have high specificity when combined with elevated TSH levels in primary hypothyroidism. Imaging modalities complement the clinical findings by evaluating structural abnormalities. Thyroid is the preferred initial imaging for assessing goiter or nodules, providing details on gland size, (often heterogeneous in autoimmune hypothyroidism), , and nodule characteristics such as hypoechogenicity or microcalcifications that raise concern. It is particularly useful when reveals or when is unclear. For suspected central hypothyroidism, (MRI) of the pituitary and is indicated to identify lesions like adenomas, infiltrative diseases, or trauma-related damage that impair TSH secretion. MRI with contrast enhances detection of sellar or parasellar masses. is reserved for suspicious nodules identified on , such as those with irregular margins or rapid growth, and is rarely needed in uncomplicated hypothyroidism. Integration of history, physical, and findings enables pattern recognition for . For instance, a family history of with a firm goiter and heterogeneous appearance points to primary hypothyroidism from Hashimoto's, while absent goiter, normal thyroid , and pituitary MRI abnormalities suggest central causes. This multifaceted approach refines and informs targeted management.

Diagnosis in Special Populations

Central hypothyroidism presents unique diagnostic challenges due to its origin in pituitary or hypothalamic dysfunction, manifesting as low free thyroxine (FT4) levels with low or inappropriately normal (TSH) concentrations. This biochemical profile contrasts with primary hypothyroidism, where TSH is markedly elevated, and requires careful differentiation to avoid misdiagnosis. In patients with suspected , the (TRH) stimulation test serves as a valuable adjunct, evaluating the pituitary's capacity to secrete TSH in response to TRH administration, particularly when baseline T4 is low. Confirmation often involves of the hypothalamic-pituitary axis alongside these hormonal assessments to identify underlying structural causes. Subclinical hypothyroidism, a milder form of thyroid underactivity, is identified by mildly elevated TSH levels ranging from 4.0 to 10.0 mU/L alongside normal FT4, with persistence confirmed over 3-6 months to exclude transient elevations. Risk stratification is essential and includes testing for thyroid peroxidase antibodies (TPOAb) to detect autoimmune predisposition, as positive antibodies increase progression risk to overt disease. Additionally, lipid profiling is recommended, given associations with elevated and triglycerides that heighten cardiovascular concerns in this population. During pregnancy, hypothyroidism diagnosis must account for trimester-specific TSH adjustments, with the first trimester upper threshold lowered to 2.5 mU/L ( 0.1-2.5 mU/L) due to physiological shifts. (hCG), peaking in early gestation, exerts thyrotropic effects by binding to TSH receptors, suppressing maternal TSH and potentially complicating interpretation of low-normal values. Subsequent trimesters see gradual normalization, with upper limits of 3.0 mU/L recommended, emphasizing the need for pregnancy-specific to guide accurate assessment. In the post-COVID-19 era, emerging evidence highlights increased incidence of new-onset autoimmune thyroid disorders, including , following infection, as documented in studies from 2023 to 2025. These cases often involve with development, prompting recommendations for function monitoring in recovering patients, particularly those with lingering symptoms or risk factors for . Serial TSH and testing can detect subclinical shifts early. Congenital hypothyroidism screening relies on universal newborn protocols, typically involving TSH measurement via heel-prick dried blood spots collected between 48 and 72 hours of life to capture postnatal surges. Elevated TSH above 40 mU/L triggers immediate recall for confirmatory serum TSH and FT4 testing, enabling prompt intervention to prevent neurodevelopmental deficits. For preterm or low-birth-weight infants at higher false-positive risk, guidelines advocate repeat screening around 2 weeks of age or simultaneous TSH/FT4 evaluation to mitigate delayed elevations.

Differential Diagnosis

The symptoms of hypothyroidism, such as fatigue, weight gain, depression, constipation, and cold intolerance, are nonspecific and overlap with those of many other conditions. Primary hypothyroidism is confirmed by elevated TSH and low free T4 levels. However, if symptoms persist despite normal or treated thyroid function tests, or if laboratory findings are atypical or nonspecific, other disorders should be considered in the differential diagnosis. Common conditions that may mimic hypothyroidism include:
  • Depression
  • Anemia (e.g., iron deficiency anemia)
  • Chronic fatigue syndrome
  • Fibromyalgia
  • Obstructive sleep apnea
  • Adrenal insufficiency (e.g., Addison disease)
  • Non-thyroidal illness syndrome (euthyroid sick syndrome)
  • Drug-induced effects (e.g., lithium)
  • Hypopituitarism
These conditions should be evaluated based on clinical context, additional history, physical examination, and targeted testing when thyroid function tests do not fully explain the presentation.

Prevention and Screening

Prevention Strategies

Ensuring adequate iodine intake is a primary strategy for preventing iodine-deficiency-related hypothyroidism, particularly in endemic areas where soil and food sources are depleted. The recommends a daily iodine intake of 150 micrograms for adults to support thyroid hormone synthesis and avert deficiency disorders. In regions with proven deficiency, universal salt iodization and targeted supplementation programs have significantly reduced goiter prevalence and hypothyroidism incidence. Limiting exposure to goitrogens, substances that interfere with iodine uptake or thyroid function, forms another key preventive measure, especially in diets reliant on high-goitrogen foods. For instance, untreated , a staple in parts of and , contains cyanogenic glycosides that can induce goiter and hypothyroidism if consumed raw or inadequately processed; proper cooking or mitigates this risk. Similarly, excessive intake of like or soy products should be moderated in iodine-deficient individuals to avoid compounding thyroid impairment. Protecting the thyroid from ionizing radiation during medical treatments for head and neck cancers is essential, as radiation exposure can damage thyroid tissue and lead to hypothyroidism in up to 50% of cases. Strategies include using lead thyroid shields during procedures and employing intensity-modulated radiation therapy to minimize glandular dose while targeting tumors. Preoperative thyroid function assessment has also shown potential in reducing radiation-induced hypothyroidism risk. For congenital hypothyroidism linked to genetic factors, and preconception testing are recommended to identify carriers of mutations, enabling informed to lower transmission risks. The 2024 European Thyroid Association guidelines emphasize molecular genetic and counseling for families with a history of genetic disorders of thyroid hormone transport, metabolism, or action, such as resistance syndromes, to guide preventive reproductive decisions. Post-COVID-19 monitoring of thyroid function is advised for individuals with autoimmune predispositions, as infection can trigger or exacerbate , potentially leading to hypothyroidism. Longitudinal studies indicate that up to 20% of recovered patients develop thyroid autoimmunity, underscoring the value of periodic TSH testing in at-risk groups to enable early intervention and prevent progression.

Screening Recommendations

Universal newborn screening for congenital hypothyroidism is recommended worldwide, utilizing a heel-prick blood sample to measure (TSH) levels, typically performed between 48 hours and 5 days after birth. This approach detects primary with high sensitivity, enabling early treatment to prevent irreversible neurodevelopmental impairments, as endorsed by consensus guidelines from the European Society for Paediatric Endocrinology. For preterm or low-birth-weight infants, a second screening at 10–14 days is advised to account for potential delayed TSH elevation. In adults, targeted TSH screening is advised for high-risk groups, including women over 60 years, individuals with a family of , and those with autoimmune conditions such as . The American Thyroid Association recommends initiating TSH screening for all adults at age 35 and repeating every 5 years thereafter, particularly emphasizing periodic evaluation in older adults to identify subclinical hypothyroidism early. However, the U.S. Preventive Services Task Force concludes there is insufficient evidence to assess the balance of benefits and harms of routine screening in nonpregnant, adults, suggesting case-finding in those with risk factors like advancing age or family . For , the American Thyroid Association guidelines recommend targeted TSH screening in the first trimester for high-risk women, using pregnancy-specific reference ranges (upper limit approximately 4.0 mU/L if trimester-specific data are unavailable), to detect overt or subclinical hypothyroidism that could impact maternal and fetal outcomes. Additional thyroid peroxidase antibody testing is recommended if TSH exceeds 2.5 mU/L in high-risk cases. Recent 2024 studies highlight associations between symptoms like persistent fatigue and dysfunction, including hypothyroidism, suggesting evaluation of function as part of a for in such individuals, given links between and autoimmunity or alterations. In such individuals, evaluating function is recommended as part of a for , given associations between and autoimmunity or alterations. Screening frequency for high-risk adults is generally every 5 years, a strategy deemed cost-effective based on decision modeling that accounts for reduced progression to overt and lowered levels with early treatment. For pregnant women, targeted first-trimester screening in high-risk groups is cost-effective, yielding an of approximately $2,655 per quality-adjusted life-year gained when subclinical hypothyroidism prevalence is around 2.5%.

Treatment

Levothyroxine Monotherapy

(LT4), a synthetic form of thyroxine (T4), serves as the cornerstone of hypothyroidism treatment, providing the primary hormone replacement to restore euthyroid status in patients with primary hypothyroidism. Administered orally, LT4 is converted peripherally to the active triiodothyronine (T3), a process that may be impaired in cases of iron deficiency due to reduced deiodinase activity and lower free T3 levels, mimicking physiological function and alleviating symptoms such as , , and cold intolerance, as well as often improving or normalizing blood pressure. Clinical guidelines emphasize its use as monotherapy for most patients, with dose adjustments guided by serum (TSH) levels to achieve normalization within the . Initial dosing for adults typically begins at 1.6–1.8 μg/kg body weight per day in otherwise healthy individuals without significant comorbidities, with subsequent every 4–6 weeks based on TSH response until stability is reached. The full replacement dose often ranges from 100–125 μg daily for women and 125–150 μg for men, accounting for differences in body mass and residual function. In patients with minimal endogenous production, such as those post-thyroidectomy, doses may need to be 20–25% higher to account for complete dependency. Optimal absorption of LT4 requires administration on an empty , ideally 60 minutes before or at least 3–4 hours after the evening meal, to maximize which can reach 60–80% under ideal conditions. Concomitant intake with food, beverages other than water, or interfering substances should be avoided; calcium supplements, iron preparations, proton pump inhibitors, and vitamin D supplements containing calcium can reduce absorption by up to 20–40% if taken within 4 hours, necessitating separation by at least 4 hours. Iron supplements, in particular, can form insoluble complexes with levothyroxine, significantly impairing its absorption, and should be administered at least 4 hours apart. There are no significant interactions between vitamin D and levothyroxine – vitamin D supplementation does not significantly affect the absorption or action of levothyroxine unless the supplement contains calcium, in which case the doses should be separated by at least 4 hours. or formulations of LT4 are recommended for patients with gastrointestinal disorders or risks, as they demonstrate superior consistency in absorption compared to tablets. Monitoring involves measuring serum TSH levels 6–8 weeks after initiating or dose changes, with adjustments made to maintain TSH within the age- and population-specific reference interval, typically 0.4–4.0 mIU/L for adults. Once euthyroidism is achieved and stable for at least 6 months, annual TSH assessments suffice, alongside clinical evaluation for symptom resolution and adverse effects like from over-replacement. Free T4 levels may be checked concurrently if TSH is unreliable, such as in non-thyroidal illness. Special considerations apply to vulnerable populations to minimize risks. In elderly patients over 65 years, initiate with a lower dose of 25–50 μg daily due to reduced , slower , and higher susceptibility to cardiac events, titrating gradually every 6–8 weeks. For those with underlying cardiac , such as ischemic heart disease or arrhythmias, start even more conservatively at 12.5–25 μg daily to avoid precipitating or from rapid hormone shifts. The 2025 European Thyroid Association () guidelines underscore the importance of using consistent LT4 preparations to ensure therapeutic reliability, recommending brand-specific or formulation-specific continuity to avoid bioinequivalence issues that could alter TSH by 10–20%. They advocate for generic LT4 only if is verified per regulatory standards, and highlight the benefits of newer and options for improved stability and reduced variability in patients prone to absorption fluctuations.

Combination and Emerging Therapies

Combination therapy with (LT4) and (LT3) is considered for patients with hypothyroidism who experience persistent symptoms, such as or , despite achieving normal (TSH) levels on LT4 monotherapy. This approach addresses potential deficiencies in tissue-level (T3) availability, particularly in individuals with genetic polymorphisms in type 2 (DIO2) enzyme, which impairs peripheral conversion of T4 to T3. Guidelines recommend initiating only after confirming adherence and optimizing LT4 dosing, with LT4 reduced by 25-50% and LT3 added at 5-7.5 μg twice daily to achieve a T4:T3 ratio approximating 13-16:1. Typical dosing involves 10-20 μg LT3 per 100 μg LT4, titrated based on TSH and symptom response. Long-term studies from 2024 indicate that LT4/LT3 can improve (QoL) measures, such as those assessed by the ThyPRO , in select patients, with sustained benefits over 2-5 years and no significant increase in adverse events like thyrotoxicosis compared to LT4 alone. A 2024 found modest enhancements in psychological and energy levels, though cardiovascular risks remain comparable if TSH is maintained within normal ranges. However, not all patients benefit, and routine use is not endorsed by major societies due to inconsistent evidence across broader populations. Desiccated thyroid extracts (DTE), derived from porcine glands, provide a natural source of both T4 and T3 in a of approximately 4:1, offering an alternative for patients dissatisfied with synthetic LT4. These extracts have variable potency due to differences in animal sourcing, processing, and degradation, leading to inconsistent and challenges in achieving stable TSH levels. In 2025, the U.S. (FDA) issued warnings against unapproved DTE products, emphasizing their lack of standardized purity and equivalence to synthetic options, and urged transition to regulated formulations. Professional organizations like the American Thyroid Association and American Association of Clinical support synthetic therapies over DTE to minimize risks of under- or overtreatment. Emerging therapies focus on improving T3 delivery and addressing underlying in hypothyroidism, particularly . Slow-release liothyronine (SRT3) formulations aim to mimic physiological T3 pulsatility and avoid peaks/troughs associated with immediate-release LT3; 2025 randomized controlled trials demonstrated that SRT3 combined with LT4 normalized serum T3 levels more effectively than LT4 monotherapy, with TSH suppression to 24-26 mIU/L and improved symptom scores in primary hypothyroidism patients over 12 weeks, without elevating or bone turnover markers. These trials reported a favorable safety profile, with ongoing studies evaluating long-term efficacy. Stem cell research for Hashimoto's thyroiditis, the leading cause of hypothyroidism, explores regenerative approaches to restore thyroid function and modulate autoimmunity. In 2025 preclinical studies, bone marrow-derived mesenchymal stem cells (MSCs) reduced thyroiditis severity in iodine-induced models by inhibiting T-cell activation, balancing Th17/Treg ratios, and alleviating oxidative stress via the STING pathway, leading to preserved thyroid architecture and hormone production. Human pluripotent stem cell-derived thyroid follicular cells showed potential for transplantation in thyroid-deficient models, secreting functional thyroid hormones and integrating into host tissue, though clinical translation remains in early phases with phase I trials anticipated by 2026. These developments highlight stem cells' immunomodulatory and regenerative promise, but large-scale human trials are needed to confirm efficacy and safety.

Subclinical Hypothyroidism

Subclinical hypothyroidism, characterized by elevated (TSH) levels with normal free thyroxine (FT4), requires individualized management based on TSH concentration, symptoms, and risk factors. Treatment with (LT4) is recommended when TSH exceeds 10 mU/L, as this threshold is associated with increased risks of and progression to overt hypothyroidism. For patients with TSH between the upper limit of normal and 10 mU/L, LT4 therapy should be considered if symptoms of hypothyroidism are present or if antibodies (TPOAb) are positive, indicating higher risk of progression (approximately 4-5% annually). A trial of LT4 therapy lasting 3-6 months is advised to assess symptom improvement and biochemical response, with dosing initiated at 25-50 mcg daily and adjusted every 4-6 weeks to normalize TSH while monitoring for over-replacement. If symptoms resolve and TSH normalizes without ongoing need, discontinuation may be trialed under monitoring, though long-term therapy is often continued in higher-risk cases to mitigate and metabolic complications.

Hypothyroidism in Pregnancy

Management of hypothyroidism during pregnancy demands prompt adjustment of LT4 to prevent adverse maternal and fetal outcomes, such as , , and neurodevelopmental delays. Women with pre-existing hypothyroidism should increase their LT4 dose by 30-50% immediately upon confirmation, as estrogen-mediated increases in elevate thyroid hormone requirements. The target TSH level is less than 2.5 mU/L in the first trimester, with trimester-specific upper limits of 3.0 mU/L in the second and third trimesters to ensure euthyroidism. For newly diagnosed overt hypothyroidism, LT4 is initiated at 1.6 mcg/kg daily, with frequent monitoring (every 4 weeks) and dose titration based on TSH and FT4 levels. Postpartum, doses are reduced to pre-pregnancy levels within 6 weeks, with TSH rechecked to avoid iatrogenic . Subclinical cases with TSH above 2.5 mU/L and positive TPOAb warrant treatment to reduce loss risk by up to 60%.

Myxedema Coma

Myxedema coma represents a life-threatening decompensation of severe hypothyroidism, necessitating immediate intensive care unit admission and multimodal therapy to achieve mortality rates below 40%. Initial treatment includes intravenous LT4 loading at 200-400 mcg (or 4 mcg/kg), followed by 50-100 mcg daily, adjusted based on clinical response and FT4 levels, as oral absorption is unreliable. Concurrent administration of hydrocortisone at 100 mg intravenously every 8 hours is essential to address potential adrenal insufficiency, which coexists in up to 30% of cases and can precipitate crisis if untreated. Supportive measures are critical, including passive rewarming to correct hypothermia (avoiding active methods to prevent vasodilation shock), mechanical ventilation for respiratory failure, intravenous fluids for hypovolemia, and empiric antibiotics for possible precipitating infection. Thyroid function tests guide ongoing therapy, with repeat LT4 dosing every 24 hours until stabilization, transitioning to oral LT4 once tolerated.

Central Hypothyroidism

Central hypothyroidism, resulting from pituitary or hypothalamic dysfunction, requires LT4 replacement guided by FT4 levels rather than TSH, as the latter may be inappropriately or low despite hormone deficiency. Dosing starts at 1.6 mcg/kg daily, titrated to maintain FT4 in the upper half of the , with monitoring every 6-8 weeks initially. Unlike primary hypothyroidism, TSH is unreliable for dose adjustment due to impaired feedback. Underlying causes, such as pituitary tumors, must be addressed concurrently; for instance, surgical resection or for adenomas, alongside for other pituitary deficiencies (e.g., , requiring replacement prior to LT4 to prevent ). In combined deficiencies, LT4 doses may need 20-30% reduction if are initiated. Long-term follow-up includes annual MRI for structural lesions and assays to prevent over- or under-replacement.

Post-COVID Hypothyroidism

Emerging evidence links to thyroid dysfunction, including hypothyroidism, potentially via direct viral effects or immune-mediated damage. LT4 is recommended symptomatically only if biochemical hypothyroidism (elevated TSH, low FT4) is verified post-infection, following standard dosing protocols adjusted for age and comorbidities. Routine screening is advised for patients with persistent or other hypothyroid symptoms 3-6 months after recovery, as transient may resolve spontaneously in 70-80% of cases. Treatment decisions incorporate ATA criteria, prioritizing LT4 monotherapy if autoimmune markers like TPOAb are present, with monitoring every 3 months to assess resolution. No unique post-COVID regimen exists; management aligns with general hypothyroidism guidelines to avoid overtreatment of non-progressive alterations.

Adjunctive Lifestyle and Dietary Measures

Levothyroxine monotherapy remains the primary and evidence-based treatment for hypothyroidism, with no scientifically proven natural methods capable of curing the condition or replacing hormone replacement therapy. Supportive measures may complement standard treatment but do not substitute for it. A diet rich in essential nutrients such as selenium (e.g., from Brazil nuts), zinc, iron, vitamin D, and adequate (but not excessive) iodine may support thyroid function. Iron deficiency is associated with lower free T3 levels and impaired conversion of T4 to active T3 due to reduced deiodinase enzyme activity. In patients with iron deficiency, particularly women or those with subclinical hypothyroidism, iron supplementation combined with levothyroxine may improve thyroid function and T3 levels more effectively than levothyroxine alone, although the evidence is limited and primarily from specific populations. Iron supplements should be taken at least 4 hours apart from levothyroxine to avoid interference with levothyroxine absorption. Vitamin D and vitamin B12 deficiencies are very common in patients with hypothyroidism treated with levothyroxine, often associated with Hashimoto's thyroiditis. Studies report vitamin B12 deficiency in approximately 27% of hypothyroid patients in meta-analyses, with rates up to 68% in some cohorts, while vitamin D insufficiency has been observed in up to 92-98% of patients with Hashimoto's thyroiditis, particularly in overt or subclinical hypothyroidism. These deficiencies overlap with hypothyroid symptoms and can exacerbate persistent fatigue, weakness, and related issues even after achieving euthyroidism with levothyroxine. Screening for vitamin D and B12 levels is often recommended in hypothyroid patients, especially those with persistent symptoms, and supplementation is frequently advised after measuring levels and in consultation with a healthcare provider. There are no significant interactions between vitamin D or vitamin B12 and levothyroxine; however, if the vitamin D supplement contains calcium, it should be taken at least 4 hours apart from levothyroxine to avoid reduced levothyroxine absorption. Excessive intake of iodine should be avoided, as it can worsen hypothyroidism in some cases. Consumption of large quantities of raw goitrogenic foods (e.g., cruciferous vegetables such as cabbage and broccoli) should be limited, as they can interfere with thyroid hormone synthesis when consumed in high amounts. Regular physical activity, stress reduction, and healthy sleep patterns can help alleviate symptoms and improve overall well-being in patients with hypothyroidism. Weight management is a common concern in patients with hypothyroidism, particularly among women who have a higher prevalence of the condition, as untreated or inadequately treated hypothyroidism can contribute to modest weight gain primarily from fluid retention and reduced basal metabolic rate. However, no dietary supplements have been proven to reliably aid weight loss specifically in patients with hypothyroidism. The most effective and evidence-based approach involves proper thyroid hormone replacement therapy (e.g., levothyroxine) to restore euthyroidism, combined with a balanced diet, calorie control, and regular exercise. While supplements such as selenium, zinc, vitamin D, or myo-inositol may support overall thyroid function or metabolism in preliminary studies (e.g., in cases of deficiency or subclinical hypothyroidism), evidence for direct weight loss benefits is limited or lacking. Products marketed as "thyroid support" or similar often contain undeclared thyroid hormones (T3 and/or T4), pose risks such as thyrotoxicosis, and have unproven claims. Patients should always consult a healthcare provider before using any supplements, as they can interfere with thyroid medications or affect thyroid function tests. While preliminary evidence from small randomized controlled trials suggests that certain herbal supplements, such as ashwagandha root extract and Nigella sativa, may help reduce TSH levels and improve thyroid function in patients with subclinical hypothyroidism or Hashimoto's thyroiditis, the evidence is limited to small studies and requires confirmation through larger trials. Supplements such as ashwagandha, Nigella sativa, or additional iodine should only be used under medical supervision, due to potential interference with levothyroxine absorption, other adverse effects, or risks such as thyrotoxicosis. Patients should always consult an endocrinologist before making dietary changes or starting supplements, as self-treatment can lead to worsening of the condition. Some patients with hypothyroidism experience a sensation of excessive mucus in the throat, often accompanied by hoarseness, swallowing difficulties, or sinus congestion, potentially attributable to fluid retention, mucosal edema, or associated sinus issues. Home remedies may provide temporary symptomatic relief for throat mucus and related discomfort. These include steam inhalation with salt or herbs, drinking herbal teas (e.g., ginger, lemon, thyme), gargling with a diluted apple cider vinegar solution, or consuming an onion-honey mixture. These measures offer only symptomatic relief and do not treat the underlying hypothyroidism, which requires medical evaluation and typically hormone replacement therapy. Patients should consult a doctor for persistent symptoms to ensure proper diagnosis and management.

Epidemiology

Prevalence and Incidence

Hypothyroidism affects up to 5% of the global , with subclinical forms comprising the majority of cases and overt hypothyroidism being less common at approximately 0.3-1%. Subclinical hypothyroidism has a of 4-10% worldwide, while overt cases range from 0.2-3.7% depending on the region and iodine status. The condition is 5-9 times more common in women than in men globally. In the United States, recent estimates using combined and Nutrition Examination Survey (NHANES) and administrative claims data, including subclinical and treated cases, indicate a of hypothyroidism of 11.7% in 2019 (up from 9.6% in 2012), higher than earlier NHANES-based figures of around 5% for diagnosed hypothyroidism; subclinical forms predominate. In iodine-deficient regions, such as parts of and , endemic hypothyroidism can affect up to 20% of the population due to severe disorders. Congenital hypothyroidism occurs in approximately 1 in 2,000 to 4,000 newborns worldwide, with higher rates in areas of iodine deficiency. The prevalence of hypothyroidism increases with age, particularly in women, reaching a peak after menopause, where subclinical cases can exceed 15% in those over 60 years. Hypothyroidism risk is notably higher in females, who are approximately five to eight times more likely to develop the condition than males, particularly due to the prevalence of autoimmune forms like Hashimoto's thyroiditis. Individuals over the age of 60 face elevated risk, with prevalence increasing progressively with age as thyroid function naturally declines and comorbidities accumulate. A personal or family history of autoimmune diseases, such as type 1 diabetes or other thyroid disorders, further amplifies susceptibility through shared genetic and immunological pathways. Environmental and iatrogenic factors also contribute significantly to risk. Iodine imbalance—either deficiency, which impairs thyroid hormone synthesis, or excess intake, which can trigger —remains a key modifiable influence, though global fortification efforts have reduced deficiency-related cases. , including from medical treatments like radioactive iodine or external beam therapy for head and neck cancers, damages thyroid tissue and predisposes individuals to hypothyroidism, with risks persisting long-term. Certain medications, notably for cardiac arrhythmias and for , interfere with thyroid hormone production or release, necessitating regular monitoring in at-risk patients. In the United States, hypothyroidism prevalence has more than doubled over the past two decades, rising from approximately 4.6% in the early to 11.7% by 2019, driven by improved diagnostics, aging demographics, and rising autoimmune incidences. Recent studies from 2023 indicate a post-COVID-19 surge in autoimmune , with prevalence nearly doubling among survivors compared to matched controls, likely due to viral-induced immune dysregulation. Globally, has declined markedly since the 1990s through widespread salt fortification programs, averting millions of cases in developing regions, while autoimmune hypothyroidism has risen in developed nations amid and environmental shifts—as of 2025 reviews estimating global prevalence at 5-10%. Projections suggest further increases in incidence, particularly as global populations age; by 2050, over 16% of the world will be 65 or older, a demographic poised to elevate hypothyroidism rates given its strong age correlation.

History

Early Descriptions

The earliest known descriptions of thyroid disorders, particularly goiter, appear in ancient medical texts from regions with . In , around 2700 BC, enlarged thyroids were noted in historical records, often associated with inland areas lacking iodine-rich . Similarly, in ancient circa 1400 BC, the Ayurvedic text referred to goiter as "galaganda," a swelling classified into types such as kaphaja, which presented features akin to hypothyroidism including and swelling. These observations linked goiter to environmental factors in iodine-poor locales, though the underlying physiological mechanisms remained unknown. Pediatric manifestations of hypothyroidism, later called cretinism, were reported in alpine Europe, where endemic goiter was prevalent. In the , (circa 1527) described individuals with goiter accompanied by intellectual impairment and developmental delays in the region of the , attributing it to local environmental influences like mineral waters. These accounts highlighted the congenital nature of the condition in iodine-deficient mountainous areas, distinguishing it from adult forms. The brought focused recognition of adult hypothyroidism in Western medicine. In 1873, British physician detailed a "cretinoid state supervening in adult life in women," characterized by dry skin, , mental dullness, and , observed in patients with atrophied glands. This description emphasized the progressive, systemic effects resembling cretinism but occurring post-puberty. Five years later, in 1878, William Miller Ord coined the term "myxoedema" for the condition, based on pathological findings of mucinous deposits in skin and thyroid atrophy, and published the first photograph of an affected patient. By the early 1890s, experimental work established the thyroid's direct role in hypothyroidism. In 1891, George Redmayne Murray, building on prior animal thyroidectomy studies that induced myxedema-like symptoms in dogs and monkeys, successfully treated a with subcutaneous sheep thyroid extract injections, confirming the gland's secretory function. These animal experiments, including those by Victor Horsley in the 1880s demonstrating after removal, provided the causal link between thyroid deficiency and the disorder.

Key Advances in Understanding and Treatment

In 1914, Edward Calvin Kendall achieved a landmark in by isolating thyroxine (T4) in crystalline form from extracts, marking the first successful purification of a and enabling further research into its physiological role. This discovery built on earlier work but provided a pure compound containing 65.3% iodine, confirming thyroxine as the active principle in function. Concurrently, the widespread adoption of desiccated extracts as a treatment for hypothyroidism in the offered a standardized, animal-derived source of , improving symptom relief for patients with and other manifestations. A pivotal milestone during this decade was the introduction of iodine iodization programs, initiated following demonstrations by David Marine and O.P. Kimball that iodine supplementation could prevent endemic goiter; by the early , iodized salt became available , dramatically reducing iodine deficiency-related disorders across goiter-prone regions. The mid-20th century saw significant therapeutic advancements with the synthesis and commercialization of (LT4), the sodium salt of thyroxine, introduced in 1949 and widely available in the United States by the 1950s, replacing variable desiccated preparations with a consistent, bioidentical that minimized risks of overdose or inconsistency. Diagnostic progress accelerated in the 1960s with the development of the first-generation radioimmunoassay (RIA) for (TSH), pioneered by Robert Utiger in 1965, which allowed sensitive detection of TSH levels and revolutionized the identification of primary hypothyroidism by distinguishing it from central causes. This assay's sensitivity enabled earlier and more precise diagnosis, shifting clinical practice from reliance on clinical symptoms and indirect measures like . From the 1970s onward, the recognition of subclinical hypothyroidism—characterized by elevated TSH with normal free T4 levels—emerged as a distinct entity, facilitated by improved TSH assays, prompting debates on screening and treatment thresholds to prevent progression to overt disease. Recent guidelines, such as the 2024 European Thyroid Association recommendations, emphasize for inherited forms like thyroid dyshormonogenesis, integrating to guide personalized management. In parallel, 2025 studies have advanced combination therapies, demonstrating that paired with slow-release (T3) can normalize tissue T3 levels and improve in select patients refractory to LT4 monotherapy.

Hypothyroidism in Animals

In Companion Animals

Hypothyroidism is a common endocrine disorder in companion animals, particularly dogs, where it represents the most prevalent hormonal imbalance affecting approximately 0.2% of the population. In cats, the condition is far less common and often arises secondarily, such as after treatment for or due to congenital factors. While the underlying mechanisms share some parallels with autoimmune , in dogs the primary cause is typically acquired destruction of the gland through lymphocytic . In dogs, certain breeds exhibit a higher predisposition, including Golden Retrievers and Doberman Pinschers, with the disorder usually manifesting between 2 and 6 years of age. Common clinical presentations include , unexplained despite normal appetite, bilateral alopecia (often starting on the trunk and sparing the head and legs), recurrent , and leading to elevated and triglycerides. These symptoms can mimic other conditions, such as allergies or nutritional deficiencies, underscoring the need for thorough veterinary evaluation. In affected cats, signs may overlap with , , and poor condition, though they are infrequently observed due to the rarity of the disease. Diagnosis in dogs relies on a combination of clinical , , and laboratory testing, with elevated serum (TSH) levels alongside low total thyroxine (T4) concentrations providing strong evidence of primary hypothyroidism. Free T4 measurement or may be used for , particularly to rule out non-thyroidal illness syndrome (), which can falsely lower T4 without true glandular dysfunction. In cats, diagnosis follows similar principles but requires caution, as iatrogenic causes must be excluded through and repeat testing to ensure persistent abnormalities. Treatment for canine hypothyroidism centers on lifelong oral supplementation with (L-T4) at an initial dose of 0.02 mg/kg body weight administered twice daily (BID), which effectively restores euthyroidism in most cases. Monitoring involves rechecking serum T4 levels 4-6 hours post-pill at 4-6 weeks, then every 6-12 months thereafter, adjusting dosage as needed to avoid iatrogenic . For cats, supplementation is reserved for confirmed cases with clinical signs, using similar L-T4 dosing titrated to response, though outcomes are generally favorable with early intervention. With consistent , affected pets often show marked improvement in energy, coat quality, and overall well-being within weeks.

In Livestock and Wildlife

Hypothyroidism in livestock is rare in adult animals but can occur congenitally due to dietary iodine deficiency, leading to goiter and associated complications across species such as cattle, sheep, goats, and horses. In cattle, congenital cases manifest as hairlessness, thickened skin (myxedema), prolonged gestation in dams, and high calf mortality, often linked to iodine-deficient forage. Sheep exhibit similar congenital hypothyroidism with goiter, apathy, hypothermia, bradycardia, diffuse alopecia, and thyroid atrophy, resulting in weak lambs that die shortly after birth. Goats affected by iodine deficiency show hairlessness, myxedema, and retarded growth in kids, with high perinatal mortality rates. In horses, naturally occurring hypothyroidism is uncommon in adults but appears congenitally in foals, often from maternal ingestion of goitrogenic plants or iodine imbalance, causing prolonged gestation, weak limbs, poor bone ossification, and a short, silky coat. Experimental induction of hypothyroidism has been achieved in all these species, confirming clinical signs like weight gain, lethargy, and coat abnormalities, but natural adult cases remain scarce and poorly documented. Diagnosis in livestock typically involves clinical history, signs such as myxedema and retarded growth, low serum thyroid hormone levels, and stimulation tests with TSH or TRH to assess response. Treatment with oral sodium levothyroxine (e.g., 10 mg daily in horses) can address symptoms, though congenital forms in foals carry a poor prognosis with no effective cure. In , hypothyroidism is infrequently reported as a pathological condition but occurs physiologically in certain species, notably during in brown bears (Ursus arctos), where levels drop significantly—total T4 to less than 44% and T3 to less than 36% of active-season values—to support metabolic suppression. This hypothyroid state in bears features decreased (to 25% of normal), , , and absence of defecation, mirroring human hypothyroidism symptoms like and without causing . Environmental contaminants can disrupt function in wild amphibians, , and birds, leading to hypothyroid-like effects such as altered development and behavior, though true hypothyroidism is rarely confirmed pathologically. In reptiles like Galápagos , iodine-poor volcanic soils increase susceptibility to hypothyroidism, presenting with and reproductive issues in affected populations. Overall, wildlife cases are understudied, with most data derived from captive or experimental contexts rather than free-ranging animals.

References

Add your contribution
Related Hubs
User Avatar
No comments yet.